AtriCure reported a 15.2% year-over-year increase in worldwide revenue, reaching $116.3 million in Q2 2024. The company also generated $8.1 million in positive cash flow during the quarter. Growth was driven by U.S. pain management, international franchises, and U.S. open appendage management.
Worldwide revenue increased by 15.2% year-over-year to $116.3 million.
U.S. revenue grew by 12.5% compared to Q2 2023, reaching $95.5 million.
International revenue increased by 29.4% to $20.7 million.
Generated positive cash flow of $8.1 million in Q2 2024.
AtriCure expects full year 2024 revenue of approximately $456 million to $461 million, reflecting growth of approximately 15% at the midpoint of the range. Management continues to expect full year 2024 Adjusted EBITDA of approximately $26 million to $29 million, with improvements annually thereafter. Full year 2024 adjusted loss per share is expected to be in the range of $0.74 to $0.82.
Visualization of income flow from segment revenue to net income
Analyze how earnings announcements historically affect stock price performance